Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2008

View Archived Issues

Preclinical studies reveal biodistribution and safety profile for NSC-715818

Further data on tubulin inhibitor LP-261 available

Progress seen in development of MEK inhibitors from Ardea Biosciences

DMS-3008 tested against lung, head and neck cancer in vitro and in vivo

Cell sensitization with KU-0060648 improves DNA damaging anticancer therapy

Novel antiangiogenic alphavbeta3 integrin antagonists developed at Allergan

Anesiva expands European license agreement for Zingo with Sigma-Tau

NCI initiates phase I trial of Dusa's Levulan PDT in oral precancerous lesions

Proteolix initiates phase II clinical trial of carfilzomib for relapsed solid tumors

Roche exercises option to further develop Memory's nicotinic alpha7 agonist MEM-3454

T-2384, a novel antidiabetic agent shows good results in preclinical studies

Amgen presents a novel c-Met inhibitor with antitumor activity in vivo

Elan outlines advances of first quarter

FDA advisory committee recommends approval of Cinryze for HAE

Febuxostat receives E.U. marketing authorization for hyperuricemia in gout

Protez commences phase II clinical study for PZ-601 in infectious diseases

Novel antiinfective agents disclosed in recent patents

Emergent BioSolutions acquires rPA-102 anthrax vaccine from VaxGen for USD 2 million

NicOx presents phase II results for PF-03187207 in glaucoma and ocular hypertension

New analgesic agents described in recent Xenon patents

N30 Pharma completes phase I clinical studies with N30-201

Recent Abbott and Merck patents report new compounds for Alzheimer's disease

Can-Fite successfully completes phase I CF-102 trial

Cell Therapeutics changes brand name of Xyotax to Opaxio

Health Canada accepts for review Basilea's NDA for alitretinoin in chronic hand eczema

GlaxoSmithKline initiates tender offer to acquire Sirtris Pharmaceuticals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...